S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Early progression in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) vs placebo (P)
    Meeting Abstract

    Reinacher-Schick, A.; Macarulla, T.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial
    Meeting Abstract

    Algul, H.; Reni, M.; Kindler, H. L.; Hammel, P.; Van Cutsem, E.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
    Meeting Abstract

    Arnold, D.; Hall, M. J.; Golan, T.; Hammel, P.; Reni, M.; Van Cutsem, E.; Macarulla, T.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • FRACTION-RCC: Innovative, high-throughput assessment of nivolumab plus ipilimumab (N+I) for treatment-refractory advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Loidl, W.; Choueiri, T. K.; Kluger, H.; George, S.; Tykodi, S. S.; Kuzel, T. M.; Perets, R.; Nair, S.; Procopio, G.; Carducci, M.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Long-term follow-up on overall survival and independent review of response in CheckMate 214: First-line nivolumab plus ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Grimm, M. O.; Tannir, N.; McDermott, D.; Escudier, B.; Hammers, H.; Frontera, O. A.; Plimack, E.; Barthelemy, P.; Neiman, V.; George, S.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1
    Meeting Abstract

    Thomas, M.; Ramalingam, S. S.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; Bernabé Caro, R.; Lee, K. H.; Zurawski, B.; Audigier-Valette, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small-cell lung cancer
    Meeting Abstract

    Gautschi, O.; Goto, K.; Oxnard, G.; Tan, D. S. W.; Loong, H. H. F.; Bauer, T.; Gainor, J.; McCoach, C.; Besse, B.; Cho, B. C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Meeting Abstract

    Kortüm, M.; Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N.; Suvannasankha, A.; Badros, A.; Libby, E.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Clinical activity of cabozantinib in patients with advanced hepatocellular carcinoma previously treated with anti-VEGF and immuno-oncology therapy: Subgroup analysis from the phase 3 CELESTIAL trial
    Meeting Abstract

    Trojan, J.; Abou-Alfa, G. K.; Cheng, A. L.; Saletan, S.; Kelley, R. K.; El-Khoueiry, A. B.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a novel therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save